...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: State of Emergency

Hartland,

This is just a short term (3 day) pharmacokinetic/safety trial in 8 healthy patients and 8 patients with severe kidney disease to show that a single dose of RVX-208 isn't metabolized any differently when kidneys are compromised. They are planning to collect blood data to analyze with the Coloroda SomaScan technology (as they did for ASSERT/ASSURE), but it will only be from this single dose over 3 days.

BearDownAZ

Share
New Message
Please login to post a reply